News Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-12 EDT			5-day change	1st Jan Change
2.275 ^USD	+0.66%		-1.52%	-1.94%

02:00pm	Transcript : Mersana Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM
05-09	Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Transcript : Mersana Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	08:00am
Mersana Therapeutics to Present at Upcoming Investor Conferences	05-22	AQ
Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	05-09	MT
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results	05-09	AQ
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05-03	AQ
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024	05-02	AQ
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04-04	AQ
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	03-19	MT
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) added to S&P Biotechnology Select Industry Index	03-17	CI
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9	02-29	MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7	02-29	MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2	02-29	MT
Transcript : Mersana Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M	02-28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	02-28	AQ
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Summary

Filters